Synthetic glucocorticoids, like dexamethasone (dex), restrict growth of the fetus and program its adult physiology, in part by altering placental phenotype. The route and timing of dex administration determine the fetal and adult outcomes,
INTRODUCTION
Synthetic glucocorticoids are widely given to pregnant women to induce maturation and improve viability of preterm infants, which account for 5%-13% of live births in developed countries [1] [2] [3] . Dexamethasone phosphate (dex) is most commonly used, given over 2 days at a dose approximately equivalent to 0.2 mg/kg/day [3] . Dex may be given as early as the 23rd week of pregnancy, and its administration may be repeated weekly in the case where the birth does not occur as early as expected [4] . Although administration is usually by injection, dex has also been given orally to pregnant women threatened with preterm birth [5] and to treat asthma, rheumatoid arthritis, and other autoimmune diseases [6, 7] . Despite the beneficial effects of synthetic glucocorticoids for neonatal viability, treatment is also associated with reduced birth weight in humans [8] , which is a significant risk factor for morbidity and mortality in the perinatal period and also in later life due to heart disease and diabetes [9, 10] .
Studies in experimental animals demonstrate that dex treatment during pregnancy causes hypertension and insulin resistance in the mature offspring in rodents, sheep, and primates [11] [12] [13] [14] [15] [16] . Moreover, the offspring are growth restricted before birth and have a smaller placenta [17] [18] [19] [20] [21] [22] [23] . Thus, maternal dex treatment may alter fetal growth by reducing the total placental supply of nutrients for tissue accretion. When exogenous glucocorticoids are given to pregnant rodents, there is reduced vasculogenesis and vessel branching in the placental labyrinth that will result in a lower capacity for oxygen diffusion to the fetus [24] [25] [26] . Furthermore, there is impaired placental accumulation of amino acids by active transport via the system A transporters [26, 27] , which are known to be important for normal fetal growth [28] . Synthetic glucocorticoid treatment also reduces the abundance of glycogen stored in the placenta [29, 30] and the secretion of placental lactogens, which are involved in the maternal metabolic adaptation to pregnancy [31] . Finally, dex lowers activity of placental 11b-hydroxysteroid dehydrogenase, the enzymatic barrier to materno-fetal transfer of natural glucocorticoids [32] . Changes in placental phenotype may therefore affect growth in utero by altering the fetal availability of specific substrates and hormones during maternal dex treatment.
The specific feto-placental outcome may, however, depend upon the timing and route of glucocorticoid administration. Studies in rats show that an abnormal postnatal phenotype is programmed in the offspring of dams given dex in late, but not early, pregnancy [12, 33] . Moreover, the placental phenotypic effects of maternal glucocorticoids depend upon the gestational age at which they are studied and are frequently delayed or different near term, even when treatment is exclusively earlier in pregnancy [26, 27, 34] . Feto-placental growth restriction is also more severe in rats when dex is given continuously in the drinking water or by osmotic minipump [18] [19] [20] than when it is given by intermittent injection at the same dose [21] . In mice, neither injection [27] nor infusion [34] of dex causes fetal growth restriction near term but there have been no reports of oral dex administration. To date, few rodent studies have examined whether there is a critical window for dex to induce changes in placental phenotype and there has been no direct comparison of the developmental effects of continuous and intermittent administration during pregnancy. Additionally, whilst recent studies have highlighted that experimental procedures like subcutaneous injection are stressors in rodents [35, 36] , little consideration has been given to whether injecting pregnant dams affects the conceptuses, even though maternal endogenous glucocorticoids are known to influence the fetal environment and modify placental function [26, [37] [38] [39] .
Therefore, the hypotheses of this study were, first, that the effects of dex on placental phenotype would depend upon whether it was given to pregnant mice orally or by injection and, second, that the outcome would reflect the combined influence of exogenous glucocorticoid and the stress of injection per se. Finally, the study tested whether placental phenotype differed when dex was given over the period of either most rapid placental or fetal growth.
Dex was administered for 5 days according to a regime commonly used in rodent studies of developmental programming [12, 33, 40] . One group of pregnant mice was given dex from Day (D) 11, when the definitive placenta is established, to D16, when it attains its maximum weight (term is D21) [41] . This treatment period encompasses the end of embryogenesis (at D16) [42] . A second group of animals was given treatment between day D14 and D19 of pregnancy, the period characterized by most rapid absolute growth of the fetus, analogous to 23-32 wk of human pregnancy when synthetic glucocorticoids are most likely given for threatened preterm delivery. Studies of placental phenotype were made at D16 and 19 in the earlier treatment group and at D19 only in the later treatment group. The morphological transport capacity of the placenta was assessed by determining the volume and vascularity of the labyrinthine zone (Lz) using stereology. Functional analyses were also made of placental system A transport by measuring the materno-fetal clearance of the neutral amino acid analog 14 C-methylaminoisobutyric acid (MeAIB). These functional measurements were related to the expression of the system A, sodium-coupled, neutral amino acid transport family of solute carriers (Slc38a1, Slc38a2, and Slc38a4). Expression of the enzymes 11b-hydroxysteroid dehydrogenase type I (Hsd11b1) and type II (Hsd11b2), along with the glucocorticoid receptor (Nr3c1), were also measured in the placenta at the mRNA level. Finally, placental transcription of vascular endothelial growth factor (Vegf) and placental lactogens-I and -II (Prl3d1 and Prl3b1) were quantified.
MATERIALS AND METHODS

Animals
All the procedures were conducted under licenses issued by the U.K. Home Office and in accordance with the Animals (Scientific Procedures) Act 1986. Pregnant C57BL6/J mice were housed in groups of two to four in 12L:12D conditions. Ad libitum food and water intake was measured daily throughout the experiment. Mice were randomly allocated to receive treatment either between D11 and D16 or between D14 and D19 of pregnancy as illustrated in Figure 1 . Animals were given one of four treatments: 47 mice were subcutaneously injected with dex (injected dex, 200 lg/kg/day, 200 ll in saline) in the interscapular region once each day; 42 mice were injected with saline only over the same period (injected control [con]); 30 mice were given dex in their drinking water (oral dex, 1 lg/ml), which they drank ad libitum from sipper bottles that were topped-up each day; the remaining 67 animals drank tap water and were not handled throughout (oral con). Daily intake of water and food was similar in all treatment groups, during and after treatment (P . 0.05). Dex dosage in orally treated mice, calculated from the daily water intake of 6.5 6 0.2 ml/day, was 226 6 15 lg/kg/day (n ¼ 6 cages).
Experimental Procedures
Mice given treatment between D11 and D16 were studied between 0800 and 1000 on D16 (n ¼ 62) while mice from all the treatment groups were studied on D19 (n ¼ 114). Unidirectional materno-fetal clearance of the nonmetabolizable system A transporter substrate, MeAIB, was measured according to previously published methods [43] . Following anesthesia with10 lg/ml fentanyl-fluanisone and midazolam (aq) (Janssen Animal Health, High Wycombe, U.K.) intraperitoneally, a 100 ll bolus of MeAIB (NEN NEC-671, specific activity 1.86 GBq/mmol) was delivered to the exposed jugular vein. Up to 4 min later, a blood sample was collected by cardiac puncture, and the dam was killed by cervical dislocation (mean time between tracer injection and blood sampling did not differ between treatment groups, P . 0.05). Blood glucose concentration was measured using a hand-held glucometer (OneTouch Ultra; Ortho-Clinical Diagnostics, High Wycombe, U.K.). The uterus was removed and the maternal carcass weighed, along with individual fetuses and placentae. The placenta closest to the mean placental weight within each litter was halved and fixed either in paraformaldehyde or glutaraldehyde solution (both 4% in 0.1 M HEPES) for histological analysis; the remaining placentae were frozen in liquid nitrogen for analysis of gene expression. Following centrifugation of the blood samples, plasma was stored at À208C.
Placental Transport of 14 
C-MeAIB
Fetuses were homogenized and digested in Biosol (National Diagnostics, Hull, U.K.) at 558C. The MeAIB content of maternal plasma and of the fetal digestates were measured by liquid scintillation counting (Optiphase Hisafe; Perkin Elmer, Cambridge, U.K. and 1216 Rackbeta; LKB Wallac, Cambridge, U.K.). Unidirectional materno-fetal clearance per gram of placenta and radioactivity accumulated per gram of fetus were calculated as described previously [43] . The coefficient of variation of replicate measurements of MeAIB content of individual samples was 8.0%.
Maternal Plasma Glucocorticoid Concentrations
Glucocorticoid concentrations were determined in maternal plasma from the cardiac blood sample collected at the time of the final study. Dex concentration was determined using a commercially available ELISA kit (Neogen Europe, Ayr, Scotland, U.K.). Serial dilution of a stock solution of dex from 10 lg/ml to 78 ng/ml was used to produce a standard concentration curve. Standards and blank and diluted (2-to 5-fold) samples were assayed in duplicate according to the manufacturer's protocol. Measured optical absorbance values were plotted against dex concentration for the standards, and the concentration of samples were determined by linear interpolation from their absorbance readings. The limit of detection of the assay was 30 ng/ml. Intra-and interassay coefficients of variation for pooled standards (mean ¼ 1.42 lg/ml) were 4.1% and 9.2%, respectively. Cross-reactivity of the assay with corticosterone was 14%.
Corticosterone concentration was measured by radioimmunoassay according to manufacturer's instructions (MP Biomedicals, Santa Ana, CA). The mean recovery of exogenous corticosterone added to phosphate buffer solution or serum at 400 ng/ml was 100.7% 6 3.1%. Intra-and interassay coefficients of variation for pooled quality controls were 7.3% (mean ¼ 193.9 ng/ml) and 6.9% (mean ¼ 248.7 ng/ml), respectively, and the lower detection limit of the assay was 7.7 ng/ml. Cross-reactivity of the assay with dex was ,0.01%. When sample corticosterone concentrations exceeded the accurate range of the assay, 2-fold dilutions were made of the sample, and the measurements were repeated.
Placental Morphometry
Paraformaldehyde-fixed placental halves (n ¼ 6 per group) were embedded in paraffin wax and exhaustively sectioned (7 lm thickness) perpendicular to the chorionic plate, then stained using a standard haematoxylin and eosin protocol. The fractional volumes of the Lz, junctional zone (Jz) and decidua basalis were determined by point counting (103 objective lens, Computer Assisted Stereological Toolbox v2.0 [Olympus, Ballerup, Denmark] and Olympus BX-50 optical microscope) on a systematic random sample of 10 sections [44] . Fractional volumes were arcsine transformed prior to statistical analysis. Fractional volumes were converted to absolute volumes in mm 3 by multiplying by total placental volume, assuming a density of 1 mg/mm 3 [25] . Glutaraldehyde-fixed placental halves were embedded in Spurr epoxy resin and a single midline section taken (1 lm thickness) and then stained with toluidine blue. Volumes of maternal and fetal blood vessels in the Lz as well as the surface area and thickness of the barrier were determined at 1003 objective using stereological methods described previously [44] .
Placental Gene Expression
Relative gene expression was determined in placentae from each treatment group by real-time PCR using the DDCt method. Total RNA was extracted from the entire placenta second closest in weight to the mean placental weight VAUGHAN ET AL. of each litter (n ¼ 6 per treatment group) using the RNeasy Plus Mini Kit (Qiagen, Crawley, U.K.), and cDNA was generated using Multiscribe Reverse Transcriptase (Applied Biosystems, Warrington, U.K.). Gene expression in each sample was analyzed in duplicate using the Applied Biosystems 7500 Fast system. The following Taqman Gene Expression Assays (Applied Biosystems) were used:
, and Prl3b1 (Mm00435852_m1). The expression of each transcript was normalized to the geometric mean of Hprt1 (Mm00446968_m1) and Sdha (Mm01352366_m1) expression, which did not vary between experimental groups.
Statistics
All the data are presented as means 6 SEM. Significance was determined at the level of P , 0.05. Fisher exact test was used to determine the association of dex treatment, either orally or by injection, with the presence of dex in the plasma. Parametric statistics were conducted separately on data from D16 and 19. Data were also analyzed separately from animals treated between D11 and D16 or between D14 and D19. The effects of treatment (con, dex), route of administration (oral, injected) were determined by two-way ANOVA. When a significant interaction between treatment and route of administration was identified, simple-effects analysis was used to determine the effect of each factor at each level of the other factor. Where data were collected for individual conceptuses, for example, feto-placental weight and MeAIB transport, each measurement within a litter was considered a replicate; therefore, litter means were calculated, such that the number of subjects was the number of litters. Pearson product-moment correlation coefficient (r) was used to determine the linear dependence of the logarithm of maternal plasma corticosterone concentration and materno-fetal MeAIB clearance. 
PLACENTAL PHENOTYPE AND DEXAMETHASONE
RESULTS
Plasma Glucocorticoid Concentrations
Because of the cross-reactivity of the dex assay with corticosterone and the high concentration of plasma corticosterone in pregnant mice [45] , dex was detected in the majority of samples assayed, irrespective of whether the dam received dex or not. However, during treatment, dex was detected at greater concentrations than that observed in controls (oral con, 156 6 23 ng/ml, n ¼ 10; injected con, 174 6 66 ng/ml, n ¼ 9) in all dams given dex orally (P ¼ 0.003, Fisher exact test; 4917 6 1349 ng/ml, n ¼ 12) but not in dams given dex by injection (P . 0.05; 171 6 28 ng/ml, n ¼ 12). Three days after dex treatment ended, dex was not detectable above control values in the plasma of dams treated via either route of administration (P ¼ 0.05; 158 6 72 ng/ml and 173 6 38 ng/ml in oral dex and injected dex dams, respectively).
Dex treatment and administration route had a significant effect on maternal levels of corticosterone during treatment at both D16 and 19 (Tables 1 and 2) . At both ages, corticosterone concentration was higher in injected animals compared to those that were not injected. At D16, dex administration by either route reduced corticosterone concentrations, relative to their respective controls, whereas at D19, corticosterone was only reduced in dams given dex orally. Three days after treatment had ended, corticosterone concentration did not differ significantly with treatment or administration route on D19 (Table  2 ). Overall, corticosterone was highest in injected control animals and lowest in dams treated orally with dex.
Maternal Weight and Blood Glucose Concentration
Dex administration between D11 and D16, by either the oral or injected route, did not affect maternal blood glucose concentration on D16 (Table 1) . However, at D19, 3 days after cessation of treatment, there was a significant effect of administration route with blood glucose concentrations significantly higher in injected than orally treated dams (Table 2 ). In contrast, dex treatment from D14 increased glucose levels at D19, irrespective of administration route (Table 2) .
Dex treatment from D11 to D16 reduced total weight of the pregnant dam and the weight of the carcass after hysterectomy at D19, but not D16 (Tables 1 and 2 ). Although treatment and route of administration did not individually affect maternal weights at D16, there was a significant interaction between the two factors (Table 1 ) with a reduced total and carcass weight at D16 in dams given dex orally (P , 0.01) but not by injection (P . 0.5) relative to their respective controls. There was a similar interaction between dex and route of administration on maternal total and carcass weight in dams treated between D14 and D19, such that dams that were dex treated orally (P , 0.01), but not by injection (P . 0.5), were lighter than their respective controls (Table 2) .
Feto-Placental Weights
Dex treatment from D11 to D16 by both routes reduced placental weight by 10%, relative to controls, at both ages studied (Tables 1 and 2 ). However, fetal weight was unaffected on D16 but was reduced by 5% on D19, 3 days after the cessation of dex treatment. In contrast, after treatment from D14 to D19 by both routes, both the fetus and placenta weighed less than controls on D19 (Table 2 ). There was therefore no independent effect of route of treatment on placental and fetal weight at either age (Tables 1 and 2 ). The number of grams of fetus per gram of placenta was always higher in dex-treated dams than in controls matched by route of administration (Tables 1 and 2 ). There was no significant effect of dex treatment or route of administration over either period on the average number of pups per litter (P[dex treatment, route, interaction] . 0.05).
Placental Morphology
Stereological methods were used to determine the volume of the Jz and Lz, and of the blood vessels and trophoblast within the Lz. The volume of the Jz was unaffected by dex treatment or administration route at D16 or D19 (Tables 3 and 4) . However, there was a significant interaction between dex treatment and route at D19 such that the Jz constituted a larger percentage of total placental volume in dams given oral (P , 0.05), but not injected (P . 0.1), dex either between D11 and D16 or D14 and D19, compared to controls (Table 4) . Jz percentage was also greater in dams injected with saline from D14 to D19 than untreated controls (P , 0.05), although dex injection had no effect per se (P . 0.05). There was no significant change in Jz absolute volume with dex treatment or route of administration at either age. PLACENTAL PHENOTYPE AND DEXAMETHASONE At D16, both the percentage and absolute volume of the Lz was reduced by dex treatment (Table 3 ). In part, this was due to the reduced volume of trophoblast and fetal blood vessels. The latter occupied a smaller percentage of the Lz in dex-treated dams (Table 3) . There was also an interaction between dex treatment and route at D16, with reduced Lz size and vascularity in dams receiving dex orally (P , 0.05) but not by injection (P . 0.05). Changes in Lz structure did not persist to D19 in dams treated between D11 and D16 (Table 4) . However, Lz volume was reduced on D19, in proportion with total placental volume, in dams given dex orally or by injection between D14 and D19, but at this gestational age, it was the percentage volume of maternal, but not fetal, blood vessels that was increased by dex (Table 4) .
Placental MeAIB Transport
On D16, neither injected nor oral dex treatment had an effect on unidirectional materno-fetal clearance and fetal accumulation of MeAIB (Fig. 2, A and C) . However, 3 days after cessation of treatment, at D19, both dex treatment (P ¼ 0.008) and route of administration (P ¼ 0.007) had interacting effects (P ¼ 0.004) such that materno-fetal MeAIB clearance was 75% greater in mice given dex orally between D11 and D16, relative to noninjected controls (P , 0.001), but was unaffected by injection of dex (P . 0.5; Fig. 2B ). Fetal accumulation of MeAIB was lower in injected than uninjected mice at D19, irrespective of whether they received dex ( Fig. 2D ). Dex treatment between D14 and D19 did not affect placental clearance or fetal accumulation of MeAIB in either orally treated or injected dams (Fig. 2, B and D) . When data from all the groups of animals treated between D11 and D16 were combined, placental MeAIB clearance was inversely correlated with maternal corticosterone at D19 (r ¼À0.40, P ¼ 0.007, n ¼ 43), but not at D16 (r ¼ 0.09, P ¼ 0.588, n ¼ 38). Neither was placental MeAIB clearance correlated with maternal corticosterone at D19, with dex treatment between D14 and D19 (r ¼ À0.40, P ¼ 0.773, n ¼ 55).
Placental Slc38a Expression
At D16, total placental expression of Slc38a1 and Slc38a2 did not vary with treatment or route of dex administration (Fig.  3) . However, there was a significant effect of administration route (P ¼ 0.004) on Slc38a4 expression, which was higher in injected than uninjected mice, irrespective of whether dams were given dex or saline. In contrast, at D19 there was no difference in Slc38a4 expression with treatment or route of administration, irrespective of the gestational age at treatment (Fig. 3) . However, dex treatment (P ¼ 0.008) and route of administration (P ¼ 0.003) between D11 and D16 were significant influences on placental Slc38a2 expression on D19, which was highest in injected controls dams and lowest in dams treated orally with dex (Fig. 3) . Slc38a1 expression was also higher in injected than uninjected dams at D19 (P , 0.001), irrespective of whether they received dex or not (Fig.  3) . There was no effect of dex treatment or its administration route on Slc38a1 and Slc38a2 expression on D19 when treatment was given between D14 and D19 (Fig. 3) .
Placental Expression of Hsd11b1, Hsd11b2, and Nr3c1
There was a significant effect of route of administration (P , 0.01), but not dex treatment (P . 0.05), on the placental expression of Hsd11b1 and Nr3c1 at D16 (Fig. 4, A and E) . Both Hsd11b1 and Nr3c1 were more highly expressed in the placentae of injected than uninjected dams. Neither administration route nor dex treatment significantly affected Hsd11b2 expression at D16 (Fig. 4C ). There were no persisting effects of route of administration or dex treatment given between D11 and D16 on expression of any of the glucocorticoid regulatory genes at D19 (Fig. 4, B, D, and F) . However, the placental expression of Hsd11b2 was increased by dex treatment between D14 and D19 (P ¼ 0.046), irrespective of administration route (P . 0.05, Fig. 4D ). There was also a significant effect of administration route per se (P ¼ 0.008) on Nr3c1 expression in the placentae of dams given the later treatment, with lower transcription in injected than noninjected dams (Fig.   FIG. 3 . Relative placental expression of Slc38a genes. Gene expression was determined by the DDCt method relative to Hprt1 and Sdha at D16 (A, C, E) and D19 (B, D, F). Significant effect (P , 0.05) of dex, denoted by *, or administration route, denoted by , by two-way ANOVA; con, open bars; oral dex, filled bars; injected con, open hatched bars; injected dex, filled hatched bars; n ¼ 6-8 per treatment group.
PLACENTAL PHENOTYPE AND DEXAMETHASONE 4F). Hsd11b1 expression was unaffected by dex treatment or administration route when given from D14 to D19 (Fig. 4B ).
Placental Expression of Vegfa, Prl3d1, and Prl3b1
Neither dex treatment nor route of administration between D11 and D16 or D14 and D19 significantly influenced placental expression of Vegf, Prl3d1, and Prl3b1 at D16 or D19 (Supplemental Table S1 , available online at www. biolreprod.org).
DISCUSSION
This study is the first to show that the intrauterine effects of giving the synthetic glucocorticoid, dex, to pregnant mice depend upon the route and timing of administration (Table 5) . Dex was administered orally or by injection either over the course of maximal placental growth, between D11 and D16, or maximal fetal growth, between D14 and D19. Oral dex administration raised maternal concentrations of plasma dex above control levels after 5 days of treatment whereas dex injection did not. On the other hand, maternal levels of the natural glucocorticoid, corticosterone, were lower during dex administration by either route and were increased by saline injection. Oral and injected dex treatments reduced placental weight at both ages and fetal weight at D19 to a similar extent. With the earlier dex treatments, placental growth restriction persisted until D19, 3 days after cessation of treatment, and was accompanied by a degree of fetal growth restriction similar to that seen with the later dex treatments. In contrast, the effects of dex on maternal body weight and glucose availability as well as materno-fetal amino acid transport were more pronounced with oral dex administration. Alterations in materno-fetal MeAIB clearance also only occurred at D19 in dams drinking dex between D11 and D16, although these were unrelated to placental Slc38a expression.. Glucocorticoid barrier function was affected by dex treatment between D14-D19 but not earlier in gestation. Therefore, whilst dex administration always restricted feto-placental growth in the mouse in the current study, placental nutrient transport and glucocorticoid barrier function depended upon the method and timing of dex administration.
The differences in plasma dex concentration between oral and subcutaneous routes of administration may relate to the timing of treatment relative to sample collection in each group of dams. Although the daily dex dosage was the same in the two groups, orally treated dams had continuous access to dex solution whereas administration was intermittent, once per day, in the injected dams. Therefore, the final dex injection was given 24 h before blood collection on D16 or D19, whereas dex solution was available for dams to drink until immediately before the study. As the plasma half-life of dex in pregnant rats is approximately 3 hours [46] , the concentration measured here will be less than the maximal level experienced by the injected dams. Indeed, in pregnant sheep, plasma dex is below the level of detection by 10 h after intramuscular injection of a similar weight-specific dose of dex [47] . Differences in the rate of absorption of dex from the gut and subcutaneous compartment may also have contributed to the differences in plasma dex seen between orally treated and injected dams in the current study. Thus, the timing and magnitude of peak dex concentration is not known in either group of mice. Nonetheless, the greater availability of dex in the plasma of orally treated dams at the time of blood collection is consistent with their lower carcass weight and suggests that there may be increased catabolism or reduced anabolism of maternal tissues when dex exposure is more prolonged.
Despite the greater plasma concentration, oral dex treatment had a similar effect on fetal and placental weight at D16 and D19, compared to dex injection. At D16, dex had little effect on fetal weight irrespective of the route of treatment even though the placenta was lighter and Lz percentage volume and Lz vascularity were reduced, in common with findings of previous studies [17, 25, 27, 34] . Reduced Lz vascularity was not associated with a reduction in Vegf expression overall, although there may have been alterations in the abundance of the specific Vegf 120 , Vegf 164 , and Vegf 188 splice isoforms, identified previously in the rodent placenta [25] . On D19, the fetuses and placentae of both dex treated groups weighed less than their respective controls, whether treatment was from D11 to D16 or D14 to D19, but fetal growth restriction was still proportionately less than that of the placenta. Previous experiments in pregnant rats indicate that the effects of PLACENTAL PHENOTYPE AND DEXAMETHASONE maternal dex on fetal growth depend on the duration of direct fetal exposure to dex [48] . More severe fetal growth restriction might, therefore, have been expected in the fetuses of dams treated orally with dex in late gestation. Because this was not the case, partitioning of resources away from the maternal carcass to the gravid uterus in the orally treated animals may have helped maintain growth of the fetuses most exposed to dex. The maternal hyperglycemia induced by dex treatment in late gestation in this and a previous study may also have increased the transplacental concentration gradient for glucose transport to the fetus at the time of its maximal growth [49] . Furthermore, the enhanced materno-fetal system A amino acid transport on D19 in dams given dex orally between D11 and D16 may have counteracted, in part, the effects of more prolonged direct exposure of the fetus to dex. Similar stimulatory effects of dex on MeAIB uptake have also been seen in human trophoblasts in vitro, although not in pregnant mice in vivo when dex is injected at lower doses over a shorter period in midpregnancy [27, 50] . However, upregulation of system A amino acid transfer is observed in the mouse placenta when its growth is restricted either naturally or by genetic or nutritional manipulation [51] [52] [53] . Indeed, in common with previous findings [51, 54] , upregulation of amino acid transport in the small dex-treated placenta may be a response to as yet unidentified demand signals from the fetus to meet its nutrient requirements for growth, particularly once dex has cleared from the circulation. Certainly, metabolic signaling from the placenta to the mother was maintained because dex had no effect on expression of the genes encoding mouse placental lactogens-I and -II, in contrast with the observations in pregnant sheep treated with betamethasone [31] . Taken together, these observations suggest that the fetal outcome of maternal dex administration reflects the combined effects of direct fetal dex exposure, the maternal metabolic responses to dex, and the placental adaptations to the ensuing degree of fetoplacental compromise. The sex of the pup may also be a factor in determining the phenotypic outcome of dex administration on the placenta because previous studies have shown gender differences in the placental adaptation to nutritional perturbations in mice [55] and synthetic glucocorticoid administration in both mice and humans [34, 56] . Changes in placental MeAIB transfer induced by dex in this and a previous study were not related to placental Slc38a gene expression [27] . Indeed, at D19 in the current study, Slc38a1 and Slc38a2 gene expression was lowest in the dams treated orally with dex between D11 and D16, which had the highest placental MeAIB transfer. Similar disparities between gene expression and activity of the placental system A transporters have also been seen in pregnant mice and rats in response to dietary manipulations, which suggests that there may be temporal dissociation between expression, translation, and trafficking of functional amino acid transporters in the placenta [53, [57] [58] [59] . The route of administration appeared to be a more important determinant of Slc38a gene expression than dex per se. Certainly, injected dams had higher placental expression of specific Slc38a isoforms than uninjected animals, when treatment was given between D11 and D16, irrespective of whether they received dex or not. This suggests that the stresses associated with injection, such as the raised concentrations of glucose, corticosterone, and other stress hormones, may influence placental Slc38a gene expression. Indeed, natural corticosterone has been reported to alter Slc38a expression in the placenta of the mouse and rat [26, 38, 60] . D16-injected dams also had higher placental expression of Hsd11b1 and Nr3c1, in common with pregnant mice and rats overexposed to natural glucocorticoids [38, 61] .
Availability of natural corticosterone may explain, in part, the functional differences observed in placental phenotype with the route of dex treatment. During treatment, maternal corticosterone concentrations were higher in injected than uninjected mice, irrespective of whether they received saline or dex, and lower in dex-treated than control dams irrespective of the route of administration. These differences are likely to result from both the stress of injection activating the hypothalamic-pituitary-adrenal axis and the negative feedback effect of dex on this axis. Coupled with the differences in placental and Nr3c1 expression between injected and uninjected dams at D16, which may persist at the protein level for some time after the cessation of treatment, these changes in circulating corticosterone concentrations mean that placental glucocorticoid exposure differs widely between the four groups. Because corticosterone is able to cross the mouse placenta in late pregnancy, fetal exposure to the natural glucocorticoid at D19 will also vary with the type and route of treatment between D11 and D16 [62] . The increased MeAIB transport across the placenta after oral dex treatment may therefore be due to lower exposure to corticosterone both at D19 and earlier in pregnancy. The inverse relationship observed between maternal corticosterone and placental MeAIB transport at D19 but not at D16 is consistent with previous findings in mice that showed maternal corticosterone is an inhibitory regulator of placental system A transport near term but not earlier in gestation [26] . It is also in keeping with the known ontogenic increase in placental Nr3c1 expression toward term [63, 64] .
Despite this, increased plasma levels of synthetic glucocorticoid did not inhibit system A transport in dams given dex between D14 and D19. Whilst increased placental expression of Hsd11b2 in these dams and in previous studies [32, 34, 65] might limit placental overexposure to natural glucocorticoids, dex is not a substrate for this enzyme. Moreover, activity of the 11bHSD2 enzyme may be reduced although its genomic expression is increased [32] . These observations may mean that regulation of materno-fetal amino acid transport is not mediated directly via placental glucocorticoid receptors. Because corticosterone also acts on mineralocorticoid receptors that have little affinity for dex, and may also influence maternal plasma aldosterone concentrations via feedback on adrenocorticotrophic hormone secretion, differences in placental function may reflect differential activation of mineralocorticoid and glucocorticoid receptors. Certainly, the mineralocorticoid aldosterone is known to influence placental growth and function in rodents and humans [66, 67] . The differences in placental transport phenotype at D19 between dams treated with dex orally and by injection are, therefore, likely to reflect a combination of the degree of dex exposure, the placental expression of 11bHSD enzymes and the glucocorticoid receptor, and the past and current availabilities of endogenous adrenal steroid hormones in the mother and fetus.
Collectively, the results show that the route and timing of administration of dex is important in determining its fetoplacental outcomes. In particular, functional rather than morphological aspects of placental development were most influenced by the route of dex treatment during the period of maximal placental growth. These findings help to explain the variable effects of dex treatment on fetal growth and intrauterine programming in previous experimental and clinical studies. They also suggest that maternal hypothalamicpituitary-adrenal function and the bioavailability of natural glucocorticoids in the feto-placental tissues may have a key role in determining the long-term consequences of dex treatment. Furthermore, the results emphasize the importance VAUGHAN ET AL.
of choosing appropriate controls in evaluating the developmental outcomes of studies using control procedures that raise endogenous glucocorticoid concentrations. These findings, therefore, have major implications both for the experimental study of prenatal glucocorticoid programming and for the clinical use of synthetic glucocorticoids during pregnancy.
